Functional constipation (FC), also known as chronic idiopathic constipation (CIC), is a common condition affecting the gastrointestinal (GI) tract, with an estimated prevalence of between 14% and 20%. This functional disorder is defined as the infrequent and difficult passage of stools in the absence of any physiological abnormality. The condition is more common in women, the elderly, and those with lower income and is associated with reduced quality of life.
Abnormal energy metabolism and mitochondrial function may be associated with the pathogenesis of constipation. Mitochondria are the main site of intracellular oxidative phosphorylation and ATP formation. Correcting mitochondrial dysfunction and improving energy metabolism disorders may be the key to enhance intestinal peristalsis. Zensun has been the first to realize the relevance between cellular energy metabolism and functional constipation. In-depth studies of the pathogenic mechanism led Zensun scientists to propose a new treatment strategy. The compound drug ZS-06, which targets multiple pathways associated with energy metabolism, was developed to utilize this strategy.
Our preclinical studies showed that ZS-06 significantly improves both the small intestine propulsion rate and defecation in animals with constipation. If the efficacy of ZS-06 is validated for the prevention and treatment of gastrointestinal motility in clinical trials, it would be useful for reducing the pain and enhancing the quality of life for patients with constipation. All ingredients in ZS-06 have been proven to be tolerable and safe in the clinic for many years, which makes it likely to be a drugable candidate, with a shorter development cycle and lower R&D costs.